Study Medication
IgA nephropathy (IgAN) is a kidney disease where abnormal antibodies build up in the kidneys. Doctors usually try to manage this disease by lowering blood pressure and protecting kidney function.
We are developing a new medicine called BHVN-1400 to help treat IgAN. This medicine is designed to remove a harmful form of the antibody IgA (called Gd-IgA) while leaving the normal, healthy IgA alone. This is important because normal IgA helps fight off infections. By targeting only the harmful IgA, BHVN-1400 may prevent kidney damage and lower the risk of infections.
BHVN-1400 is made using advanced technology that allows it to attach to the harmful IgA and send it to the liver, where it can be safely broken down. This approach is new and could offer hope to people with IgAN by slowing or even stopping the disease.
Administration of the Study Medication
The study lasts for 114 days with 12 visits. The drug will be administered with an injection under the skin.